Overskridelsesundersøgelse for deltagere, der har gennemført en tidligere klinisk undersøgelse med benralizumab (Fasenra) og drager fordel af fortsat behandling (ROSY-F)
ROSY-F: Roll-Over-undersøgelse for deltagere, der har gennemført en tidligere undersøgelse med Benralizumab (Fasenra) og som af undersøgeren vurderes at have klinisk fordel af fortsat behandling
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This will be an open-label, non-randomised, multicentre, international study for eligible participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment as judged by the Investigator. Any clinical study conducted with benralizumab (Fasenra) for indications such as asthma, EGPA, HES and future indications from additional parent studies, is potentially a parent study.
Each participant continuing to receive clinical benefit from benralizumab but with no access to the drug after exiting the parent study must be seen at the Investigator site, offered the opportunity to transition to the ROSY-F. The duration of clinical benefit from study treatment for an individual participant can exceed the duration of a clinical trial. To ensure continued supply of treatment to a participant who, as judged by the Investigator, is still receiving benefit when he/she either completes or exits the parent study or when the parent study closes, a roll-over study is the most universally acceptable mechanism for continuing to provide ongoing study treatment.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1121ABE
- Rekruttering
- Research Site
-
Florida, Argentina, B1602DQD
- Rekruttering
- Research Site
-
Lobos, Argentina, 7240
- Ikke rekrutterer endnu
- Research Site
-
Mar del Plata, Argentina, B7600FYK
- Rekruttering
- Research Site
-
Mendoza, Argentina, 5500
- Rekruttering
- Research Site
-
Mendoza, Argentina, M5500
- Rekruttering
- Research Site
-
Rosario, Argentina, 2000
- Rekruttering
- Research Site
-
San Juan Bautista, Argentina, 1888
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Brussels, Belgien, 1070
- Rekruttering
- Research Site
-
Edegem, Belgien, B-2650
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- Ikke rekrutterer endnu
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- Rekruttering
- Research Site
-
Toronto, Ontario, Canada, M5G 1E2
- Rekruttering
- Research Site
-
Toronto, Ontario, Canada, M5G 1X8
- Ikke rekrutterer endnu
- Research Site
-
Toronto, Ontario, Canada, M5T 3A9
- Rekruttering
- Research Site
-
-
-
-
-
London, Det Forenede Kongerige, W2 1NY
- Rekruttering
- Research Site
-
-
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Ikke rekrutterer endnu
- Research Site
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20892
- Ikke rekrutterer endnu
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48105
- Ikke rekrutterer endnu
- Research Site
-
-
New Jersey
-
Northfield, New Jersey, Forenede Stater, 08225
- Ikke rekrutterer endnu
- Research Site
-
-
New York
-
The Bronx, New York, Forenede Stater, 10459
- Ikke rekrutterer endnu
- Research Site
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Ikke rekrutterer endnu
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Bron, Frankrig, 69677
- Ikke rekrutterer endnu
- Research Site
-
Marseille, Frankrig, 13915
- Rekruttering
- Research Site
-
Montpellier, Frankrig, 34090
- Rekruttering
- Research Site
-
Nantes, Frankrig, 44093
- Rekruttering
- Research Site
-
Paris, Frankrig, 75014
- Rekruttering
- Research Site
-
Paris, Frankrig, 75018
- Rekruttering
- Research Site
-
Pessac, Frankrig, 33604
- Rekruttering
- Research Site
-
Suresnes, Frankrig, 92151
- Rekruttering
- Research Site
-
-
-
-
-
Rotterdam, Holland, 3015 GD
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Ahmedabad, Indien, 380052
- Trukket tilbage
- Research Site
-
Ajmer, Indien, 305001
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Haifa, Israel, 34362
- Rekruttering
- Research Site
-
Holon, Israel, 5822012
- Rekruttering
- Research Site
-
Petah Tikva, Israel, 492025
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Roma, Italien, 00165
- Trukket tilbage
- Research Site
-
-
-
-
-
Chęciny, Polen, 26-060
- Ikke rekrutterer endnu
- Research Site
-
Gdansk, Polen, 80-214
- Ikke rekrutterer endnu
- Research Site
-
Lodz, Polen, 90-302
- Trukket tilbage
- Research Site
-
Lodz, Polen, 90-153
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Incheon, Sydkorea, 400-711
- Rekruttering
- Research Site
-
-
-
-
-
Istanbul, Tyrkiet (Türkiye), 34093
- Ikke rekrutterer endnu
- Research Site
-
-
-
-
-
Innsbruck, Østrig, 6020
- Ikke rekrutterer endnu
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
1. Provision of signed and dated written ICF.
2. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment.
-
3. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment.
-
4. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment.
-
5. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation.
Exclusion Criteria:
- 1. Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting benralizumab.
- 2. Participants who are planning to use live/live-attenuated vaccines.
- 3. Participants who are planning to use biologic therapies, including B-cell therapies with the exception for the treatment of co-morbidities where no alternative medicine is available.
- 4. Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
- 5. Concurrently enrolled in any clinical study (other than a parent study).
- 6. Participants who discontinued the parent study prior to completing the minimum OLE or treatment period.
- 7. Local access to commercially available benralizumab.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Benralizumab arm
Benralizumab will be administrated as an subcutaneous injection at a frequency in line with that received in the parent study. |
Accessorized Pre-Filled Syringe (Solution for injection).
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab
Tidsramme: From baseline until 8 weeks after the last dose of benralizumab
|
To provide benralizumab to participants who continue to benefit at the end of the parent clinical study while monitoring long-term safety and tolerability of benralizumab |
From baseline until 8 weeks after the last dose of benralizumab
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Luftvejssygdomme
- Lungesygdomme
- Bronchiale sygdomme
- Lungesygdomme, obstruktiv
- Respiratorisk overfølsomhed
- Overfølsomhed, Øjeblikkelig
- Overfølsomhed
- Eosinofili
- Leukocytlidelser
- Hæmatologiske sygdomme
- Hudsygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Hudsygdomme, vaskulære
- Vaskulitis
- Anti-neutrofil cytoplasmatisk antistof-associeret vaskulitis
- Granulom
- Systemisk vaskulitis
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Astma
- Hypereosinofilt syndrom
- Churg-Strauss syndrom
- Benralizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D3250N00036
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .